ALZAMEND NEURO, INC. Amortization of Debt Discount (Premium)
ALZAMEND NEURO, INC. (ALZN) reported Amortization of Debt Discount (Premium) of $9.29 thousand for the 12-month period ending 2025-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-07-22
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for the quarter ending 2025-04-30 was $0.00.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for the quarter ending 2025-01-31 was $0.00.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for the quarter ending 2024-10-31 was $0.00.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for the quarter ending 2024-07-31 was $9.29K.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for fiscal 2025 was $9.29K, a 1200.56% increase from fiscal 2024.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for fiscal 2024 was $714.00.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for fiscal 2022 was $12.77K, a 89.71% decline from fiscal 2021.
- ALZAMEND NEURO, INC. amortization of debt discount (premium) for fiscal 2021 was $124.05K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2025-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $0.00 derived: sum of 2 quarters · filed 2026-07-22 | $0.00 derived: sum of 3 quarters · filed 2026-07-22 | $9.29K 10-K · filed 2026-07-22 |
| 2025-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $9.29K 10-Q · filed 2026-03-11 | |
| 2024-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $9.29K 10-Q · filed 2025-12-09 | ||
| 2024-07-31 | $9.29K 10-Q · filed 2025-09-10 | |||
| 2024-04-30 | $714.00 10-K · filed 2025-07-22 | |||
| 2022-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | -$16.85K derived: sum of 2 quarters · filed 2023-07-27 | $7.97K derived: sum of 3 quarters · filed 2023-07-27 | $12.77K 10-K · filed 2023-07-27 |
| 2022-01-31 | -$16.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-15 | $7.97K derived: sum of 2 quarters · filed 2023-03-15 | $12.77K 10-Q · filed 2023-03-15 | $39.37K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-10-31 | $24.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-12 | $29.62K 10-Q · filed 2022-12-12 | $56.22K derived: sum of 3 quarters · filed 2022-12-12 | $108.04K derived: sum of 4 quarters · filed 2022-12-12 |
| 2021-07-31 | $4.79K 10-Q · filed 2022-09-13 | $31.39K derived: sum of 2 quarters · filed 2022-09-13 | $83.22K derived: sum of 3 quarters · filed 2022-09-13 | |
| 2021-04-30 | $26.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $78.42K derived: sum of 2 quarters · filed 2022-07-19 | $124.05K 10-K · filed 2022-07-19 | |
| 2021-01-31 | $51.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $97.45K 10-Q · filed 2022-03-15 | ||
| 2020-10-31 | $45.63K 10-Q · filed 2021-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |